Literature DB >> 33542188

Overexpressed P75CUX1 promotes EMT in glioma infiltration by activating β-catenin.

Anqi Xu1, Xizhao Wang2, Jie Luo1, Mingfeng Zhou1, Renhui Yi3, Tengyue Huang3, Jie Lin1, Zhiyong Wu4, Cheng Xie1, Shengfeng Ding1, Yu Zeng5, Ye Song6.   

Abstract

The homeobox protein cut-like 1 (CUX1) comprises three isoforms and has been shown to be involved in the development of various types of malignancies. However, the expression and role of the CUX1 isoforms in glioma remain unclear. Herein, we first identified that P75CUX1 isoform exhibited consistent expression among three isoforms in glioma with specifically designed antibodies to identify all CUX1 isoforms. Moreover, a significantly higher expression of P75CUX1 was found in glioma compared with non-tumor brain (NB) tissues, analyzed with western blot and immunohistochemistry, and the expression level of P75CUX1 was positively associated with tumor grade. In addition, Kaplan-Meier survival analysis indicated that P75CUX1 could serve as an independent prognostic indicator to identify glioma patients with poor overall survival. Furthermore, CUX1 knockdown suppressed migration and invasion of glioma cells both in vitro and in vivo. Mechanistically, this study found that P75CUX1 regulated epithelial-mesenchymal transition (EMT) process mediated via β-catenin, and CUX1/β-catenin/EMT is a novel signaling cascade mediating the infiltration of glioma. Besides, CUX1 was verified to promote the progression of glioma via multiple other signaling pathways, such as Hippo and PI3K/AKT. In conclusion, we suggested that P75CUX1 could serve as a potential prognostic indicator as well as a novel treatment target in malignant glioma.

Entities:  

Year:  2021        PMID: 33542188      PMCID: PMC7862635          DOI: 10.1038/s41419-021-03424-1

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  59 in total

1.  IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.

Authors:  Felipe J Núñez; Flor M Mendez; Padma Kadiyala; Mahmoud S Alghamri; Masha G Savelieff; Maria B Garcia-Fabiani; Santiago Haase; Carl Koschmann; Anda-Alexandra Calinescu; Neha Kamran; Meghna Saxena; Rohin Patel; Stephen Carney; Marissa Z Guo; Marta Edwards; Mats Ljungman; Tingting Qin; Maureen A Sartor; Rebecca Tagett; Sriram Venneti; Jacqueline Brosnan-Cashman; Alan Meeker; Vera Gorbunova; Lili Zhao; Daniel M Kremer; Li Zhang; Costas A Lyssiotis; Lindsey Jones; Cameron J Herting; James L Ross; Dolores Hambardzumyan; Shawn Hervey-Jumper; Maria E Figueroa; Pedro R Lowenstein; Maria G Castro
Journal:  Sci Transl Med       Date:  2019-02-13       Impact factor: 17.956

2.  The roles of CUX1 homeodomain proteins in the establishment of a transcriptional program required for cell migration and invasion.

Authors:  Valérie Kedinger; Alain Nepveu
Journal:  Cell Adh Migr       Date:  2010-07-04       Impact factor: 3.405

3.  HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma.

Authors:  Hong Li; Junjie Li; Lei Chen; Songtao Qi; Shishi Yu; Zhijian Weng; Ziyou Hu; Qiang Zhou; Zong Xin; Linyong Shi; Liyi Ma; Annie Huang; Yuntao Lu
Journal:  Clin Cancer Res       Date:  2019-03-12       Impact factor: 12.531

4.  Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.

Authors:  Chantal Cadieux; Valérie Kedinger; Lu Yao; Charles Vadnais; Maria Drossos; Marilène Paquet; Alain Nepveu
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

5.  CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.

Authors:  Meiling Zhang; Qian Wang; Yan Ding; Guoqun Wang; Yunqian Chu; Xiang He; Xue Wu; Yang W Shao; Kaihua Lu
Journal:  J Thorac Oncol       Date:  2018-08-07       Impact factor: 15.609

6.  Targeting the Nuclear Cathepsin L CCAAT Displacement Protein/Cut Homeobox Transcription Factor-Epithelial Mesenchymal Transition Pathway in Prostate and Breast Cancer Cells with the Z-FY-CHO Inhibitor.

Authors:  Liza J Burton; Jodi Dougan; Jasmine Jones; Bethany N Smith; Diandra Randle; Veronica Henderson; Valerie A Odero-Marah
Journal:  Mol Cell Biol       Date:  2017-02-15       Impact factor: 4.272

7.  EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.

Authors:  C Depner; H Zum Buttel; N Böğürcü; A M Cuesta; M R Aburto; S Seidel; F Finkelmeier; F Foss; J Hofmann; K Kaulich; S Barbus; M Segarra; G Reifenberger; B K Garvalov; T Acker; A Acker-Palmer
Journal:  Nat Commun       Date:  2016-07-29       Impact factor: 14.919

8.  Immune phenotypes predict survival in patients with glioblastoma multiforme.

Authors:  Haouraa Mostafa; Andrej Pala; Josef Högel; Michal Hlavac; Elvira Dietrich; M Andrew Westhoff; Lisa Nonnenmacher; Timo Burster; Michael Georgieff; C Rainer Wirtz; E Marion Schneider
Journal:  J Hematol Oncol       Date:  2016-09-01       Impact factor: 17.388

9.  Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Authors:  James J Harding; Maeve A Lowery; Alan H Shih; Juan M Schvartzman; Shengqi Hou; Christopher Famulare; Minal Patel; Mikhail Roshal; Richard K Do; Ahmet Zehir; Daoqi You; S Duygu Selcuklu; Agnes Viale; Martin S Tallman; David M Hyman; Ed Reznik; Lydia W S Finley; Elli Papaemmanuil; Alessandra Tosolini; Mark G Frattini; Kyle J MacBeth; Guowen Liu; Bin Fan; Sung Choe; Bin Wu; Yelena Y Janjigian; Ingo K Mellinghoff; Luis A Diaz; Ross L Levine; Ghassan K Abou-Alfa; Eytan M Stein; Andrew M Intlekofer
Journal:  Cancer Discov       Date:  2018-10-24       Impact factor: 38.272

10.  Autocrine Activation of the Wnt/β-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers.

Authors:  Charles Vadnais; Peiman Shooshtarizadeh; Charles V Rajadurai; Robert Lesurf; Laura Hulea; Sayeh Davoudi; Chantal Cadieux; Michael Hallett; Morag Park; Alain Nepveu
Journal:  Biol Open       Date:  2014-09-12       Impact factor: 2.422

View more
  4 in total

Review 1.  Cancer Metabolism: The Role of Immune Cells Epigenetic Alteration in Tumorigenesis, Progression, and Metastasis of Glioma.

Authors:  Kouminin Kanwore; Konimpo Kanwore; Gabriel Komla Adzika; Ayanlaja Abdulrahman Abiola; Xiaoxiao Guo; Piniel Alphayo Kambey; Ying Xia; Dianshuai Gao
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

2.  DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin.

Authors:  Yi Liu; Jun Ma; Jiu-Shan Song; Hai-Ying Zhou; Jing-Hui Li; Cheng Luo; Xin Geng; He-Xiang Zhao
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

3.  MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma.

Authors:  Ji Wang; Yanming Chen; Qing Wang; Hui Xu; Chunwang Wu; Qianqian Jiang; Guoqing Wu; Honglong Zhou; Zongyu Xiao; Ying Chen; Tan Zhang; Qing Lan
Journal:  Cell Death Dis       Date:  2022-04-18       Impact factor: 9.685

4.  Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response.

Authors:  Nan Wang; Xin Gao; Hang Ji; Shuai Ma; Jiasheng Wu; Jiawei Dong; Fang Wang; Hongtao Zhao; Zhihui Liu; Xiuwei Yan; Bo Li; Jianyang Du; Jiheng Zhang; Shaoshan Hu
Journal:  Front Mol Biosci       Date:  2022-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.